{"id":"W2910270132","doi":"10.1136/annrheumdis-2018-eular.6758","title":"AB0903 Efficacy of tildrakizumab in etanercept partial or nonresponders","year":2018,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of British Columbia; Probity Medical Research","funders":"Merck Sharp and Dohme; EMD Serono; Kyowa Hakko Kirin; Dermira; Meiji Seika Pharma; Pfizer; Novartis Pharmaceuticals Corporation; Celgene; Genentech; Valeant Pharmaceuticals International; Sanofi; Amgen; Eli Lilly and Company; GlaxoSmithKline; Sun Pharma; Regeneron Pharmaceuticals; American Academy of Dermatology","keywords":"Medicine; Etanercept; Psoriasis; Internal medicine; Psoriasis Area and Severity Index; Placebo; Gastroenterology; Dermatology; Tumor necrosis factor alpha; Pathology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004539949,0.0002132376,0.001047517,0.0002027133,0.0001636637,0.000343272,0.0002319249,0.0003276227,0.002698164],"category_scores_gemma":[0.0004348222,0.000121409,0.0005213955,0.0001217989,0.0001777084,0.0003157336,0.0000942243,0.0008252308,0.0005730693],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002164867,"about_ca_system_score_gemma":0.0002151787,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004987928,"about_ca_topic_score_gemma":0.0009058935,"domain_scores_codex":[0.9997972,0.00006799906,0.00002375079,0.00002409529,0.00002411329,0.00006295113],"domain_scores_gemma":[0.9997746,0.00006574213,0.00003316381,0.00002754222,0.00001621542,0.00008276526],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3533251,0.01472534,0.02605715,0.0008407228,0.001314077,0.001597036,0.0002433012,0.001025386,0.1557308,0.0003855417,0.003179576,0.4415761],"study_design_scores_gemma":[0.1134712,0.4260881,0.3990881,0.0002640913,0.002522223,0.005147144,0.0004450568,0.003743368,0.03448856,0.0005943884,0.01406552,0.0000823627],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.99577,0.002144068,0.00006866124,0.0001318281,0.00006483257,0.00004846921,0.0001332781,0.00003764393,0.001601216],"genre_scores_gemma":[0.998165,0.000536491,0.00009493214,0.000132807,0.00004054701,0.00002448783,0.0001677461,0.000004420444,0.0008335653],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002698164,"threshold_uncertainty_score":0.009026229,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05526279902356336,"score_gpt":0.317720676704457,"score_spread":0.2624578776808936,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}